The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.

Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.

cls.cnAug 28 19:29 ET

The performance has "double declined" and the stock price "continues to fall". Why did bloomage biotechnology corporation limited's growth engine stall?

① Bloomage Biotechnology Corporation Limited once again experienced a double decline in revenue and net income in the first half of the year. The company achieved revenue of 2.81 billion yuan, a year-on-year decrease of 8.61%; achieved net income of 0.342 billion yuan, a year-on-year decrease of 19.51%; ② Although the raw materials business and medical terminal business performed well, the two major new sectors that have been heavily promoted in recent years - functional skincare products and functional food - have experienced a simultaneous decline in growth rates.

cls.cnAug 23 22:23 ET

High inventory combined with industry pressure, Chongqing Taiji Industry's H1 revenue and net profit both declined | Interpretations

In the first half of this year, Chongqing Taiji Industry's net profit was 0.495 billion yuan, a year-on-year decrease of 12.51%. The company stated that the poor performance in the first half of the year was mainly due to the high base of the same period last year and the high social inventory of some products.

cls.cnAug 22 11:19 ET

The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.

①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.

cls.cnAug 21 10:16 ET

Shanghai Haohai Biological Technology released its semi-annual report: hyaluronic acid product revenue increased by over 50% year-on-year, while revenue from multiple product lines in ophthalmology decreased.

Regarding new products, Shanghai Haohai Biological Technology has successfully obtained approval for the world's first organic cross-linked hyaluronic acid product 'Haimei Yuebai' developed globally in July this year, while the Asia Vets cross-linked collagen product entered the registration and inspection stage in June. Due to the selected price decline in the quantity-based procurement of artificial crystalline lenses, sales revenue decreased year-on-year. As for the consumer market, it is showing signs of fatigue coupled with an increase in the number of competing products, resulting in a decline in revenue from corneal shaping lens business.

cls.cnAug 16 09:23 ET

Meituan sets its sights on small businesses like nail salons.

Explore the potential of the industry chain.

wallstreetcnAug 2 08:22 ET